Literature DB >> 29428362

Changes in antimicrobial resistance and demographics of UTIs in pediatric patients in a single institution over a 6-year period.

B Erol1, M Culpan2, H Caskurlu3, U Sari2, Y Cag3, H Vahaboglu3, S H Özumut4, M I Karaman2, T Caskurlu2.   

Abstract

PURPOSE: To determine changes in antimicrobial resistance and demographics of UTIs in pediatric patients in a single institution over a 6-year period.
MATERIALS AND METHODS: The current study examined outpatient urinary isolates from patients aged <18 years. A retrospective cross-sectional analysis of bacteria isolated from children with UTI was performed between 2009 and 2014. The most common bacterial pathogens were determined in the following four age groups: <2 years; 2-5 years; 6-12 years; and 13-17 years. The study analyzed the prevalence and antibiotic resistance patterns for the six most common uropathogens: Escherichia coli, Proteus, Klebsiella, Enterobacter, Pseudomonas and Enterococcus (Summary table). The antibiotic resistance pattern for UTI during 2009-2014 was also examined.
RESULTS: A total of 6515 urinary cultures was examined. The majority of these isolates were from female patients (66.8%). E. coli was the most common uropathogen overall, but the prevalence of E. coli was higher among females (79.5%) than males (54.9%). The biggest percentage of isolates in males was from children aged <2 years (46.1%). Conversely, the majority of isolates in females were from children aged >6 years (46.8%). Results of antimicrobial resistance for E. coli were the highest for ampicillin (70%) and lowest for meropenem (0.19%). Comparing the hospital network data from 2009 to 2014, E. coli resistance increased for ampicillin (from 47.1% to 89%), trimethoprim-sulfamethoxazole (TMP-SMX) (from 44.8% to 56%) and nitrofurantoin (from 5.3% to 15.1%). In contrast, cephalosporins have maintained low antibiotic resistance.
CONCLUSION: UTI in females was nearly twice as common than in males. E. coli remained the most common pediatric uropathogen. Although widely used in other tract infections, ampicillin was a poor empiric choice for pediatric UTIs. Cephalosporins were appropriate alternatives given their low resistance rates. A successful empirical treatment protocol should be based on local epidemiology and susceptibility rates.
Copyright © 2018 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Bacterial species; Pediatric urinary infection

Mesh:

Substances:

Year:  2018        PMID: 29428362     DOI: 10.1016/j.jpurol.2017.12.002

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  5 in total

1.  A decade of trends in the distribution and antimicrobial susceptibility of prevalent uropathogens among pediatric patients from Tehran, Iran during 2005-2016.

Authors:  Ali Reza Nateghian; Sina Karaji; Khosrow Zamani
Journal:  Asian J Urol       Date:  2020-05-29

Review 2.  Current status of long-term antibiotic prophylaxis for urinary tract infections in children: An antibiotic stewardship challenge.

Authors:  Sarah S Alsubaie; Mazin A Barry
Journal:  Kidney Res Clin Pract       Date:  2019-12-31

3.  Antibiotic Resistance and Bacteria in Urinary Tract Infections in Pediatric Patients.

Authors:  Yakup Cag; Demet Haciseyitoglu; Abdurrahman Avar Ozdemir; Yasemin Cag
Journal:  Medeni Med J       Date:  2021-09-30

4.  Prevalence and Resistance Patterns of Pediatric Urinary Tract Infections in Bahrain.

Authors:  Omaima A Shaaban; Nermin A Mahmoud; Anas A Zeidan; Nitya Kumar; Alan C Finan
Journal:  Cureus       Date:  2021-12-31

5.  Resistance Patterns from Urine Cultures in Children Aged 0 to 6 Years: Implications for Empirical Antibiotic Choice.

Authors:  Carlotta Montagnani; Chiara Tersigni; Sara D'Arienzo; Andreea Miftode; Elisabetta Venturini; Barbara Bortone; Leila Bianchi; Elena Chiappini; Silvia Forni; Fabrizio Gemmi; Luisa Galli
Journal:  Infect Drug Resist       Date:  2021-06-23       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.